samedan logo
 
 
 
spacer
home > ebr > spring 2004 > a review of burrill & company's 18th annual report on the biotech industry
PUBLICATIONS
European Biopharmaceutical Review

A Review of Burrill & Company's 18th Annual Report on the Biotech Industry

"While revaluation and restructuring defined 2002, the biotech industry made a dramatic recovery in 2003 getting 'back on track'", notes G Steven Burrill at the start of Burrill & Company's 18th annual report on the biotechnology industry. The 450 page compendium details all the important events, discoveries and financial activity in the various sectors of the biotechnology industry during 2003. G Steven Burrill, CEO of Burrill & Company and a respected biotech investment visionary, identifies the key trends and outlook for this increasingly vital and important industry. Burrill's book is a valuable resource of state-of-the-industry data and statistics with insight on where the various areas of the life sciences are headed.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Crispin Littlehales, Freelance Biotech Writer

Crispin Littlehales has been a freelance writer in the analytical chemistry and biotechnology fields for 18 years. She is regularly published in a variety of publications including Analytical Chemistry, American Lab, American Genomics/Proteomics Technology, Genetic Engineering News, Modern Drug Discovery and Today's Chemist at Work. She received her BA in Archaeology from Princeton University.

spacer
Crispin Littlehales
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

SGS Enrolls First Patient into Biophytis’ COVA Clinical Study, a COVID-19 Clinical Trial

SGS was chosen by French biotech company Biophytis to conduct its COVA study – a Clinical Trial with Sarconeos (BIO101) for the Treatment of Patients with COVID-19 Related Respiratory Failure.
More info >>

White Papers

Utilising Big Data to Produce Faster and Cheaper Clinical Research

Medical Research Network (MRN) Limited

Recruitment and retention of patients remains the major challenge to ensuring trials run as fast as possible and give them the statistical power they are designed to produce. This is not just about getting better any more - but about stopping the deterioration of these metrics in modern clinical trials.
More info >>

 
Industry Events

BIO-Europe Digital

26-29 October 2020, Digitally delivered

Global connections are more important than ever. With the same powerful one-to-one partnering and valuable content, BIO-Europe Digital continues to help you drive your life science partnering forward.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement